Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next

Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next

Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3 trial, joining two others that are already in phase 3 development.

Metric

Q3 2017

Continue reading

Source: Fool.com